MedTrace Logo

Hypofractionated Accelerated Radiotherapy for Low Risk Localized Prostate Cancer

NCT01578902 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2020-12-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the safety and efficacy of a short course of radiotherapy (35 Gy / 5 fractions / 29 days) for the treatment of low-risk prostate cancer.

Conditions

Interventions

RADIATION

Stereotactic ablative body radiotherapy

35Gy/5 fractions/29 days

Sponsors & Collaborators

  • Canadian Association of Radiation Oncology

    collaborator INDUSTRY

  • Sunnybrook Health Sciences Centre

    lead OTHER

Principal Investigators

  • Andrew Loblaw, MD · Sunnybrook Health Sciences Centre

  • Patrick Cheung, MD · Sunnybrook Health Sciences Centre

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2008-04-30
Completion
2013-04-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01578902 on ClinicalTrials.gov